EP3270963A4 - Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections - Google Patents
Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections Download PDFInfo
- Publication number
- EP3270963A4 EP3270963A4 EP16765794.9A EP16765794A EP3270963A4 EP 3270963 A4 EP3270963 A4 EP 3270963A4 EP 16765794 A EP16765794 A EP 16765794A EP 3270963 A4 EP3270963 A4 EP 3270963A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- vaccines
- adjuvants
- compositions
- treatment
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/660,523 US9149521B2 (en) | 2013-09-25 | 2015-03-17 | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
US201562135092P | 2015-03-18 | 2015-03-18 | |
US14/800,003 US9415097B2 (en) | 2013-09-25 | 2015-07-15 | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
PCT/US2016/022977 WO2016149558A2 (en) | 2015-03-17 | 2016-03-17 | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3270963A2 EP3270963A2 (en) | 2018-01-24 |
EP3270963A4 true EP3270963A4 (en) | 2018-08-22 |
Family
ID=56919421
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16765693.3A Withdrawn EP3270962A4 (en) | 2015-03-17 | 2016-03-16 | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
EP16765794.9A Withdrawn EP3270963A4 (en) | 2015-03-17 | 2016-03-17 | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16765693.3A Withdrawn EP3270962A4 (en) | 2015-03-17 | 2016-03-16 | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
Country Status (3)
Country | Link |
---|---|
EP (2) | EP3270962A4 (en) |
CN (2) | CN107405395A (en) |
WO (2) | WO2016149417A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030199071A1 (en) * | 2000-12-08 | 2003-10-23 | Solomon Langermann | Mutant proteins, high potency inhibitory antibodies and fimch crystal structure |
US20080131466A1 (en) * | 2006-09-26 | 2008-06-05 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
US20130273149A1 (en) * | 2012-04-12 | 2013-10-17 | Ac Immune Sa | Disaccharide synthetic lipid compounds and uses thereof |
WO2015044886A2 (en) * | 2013-09-25 | 2015-04-02 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4912094B1 (en) * | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
DK1075276T3 (en) * | 1998-05-07 | 2008-02-11 | Corixa Corp | Adjuvant composition and methods for its use |
AU2001218049A1 (en) * | 2000-08-18 | 2002-03-04 | Med Immune, Inc. | Method of administering fimh protein as a vaccine for urinary tract infections |
US20090181078A1 (en) * | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
US9669060B2 (en) * | 2009-04-23 | 2017-06-06 | Cornell University | Compositions for preventing and treating uterine disease |
BR112012000826B1 (en) * | 2009-07-06 | 2022-07-26 | Variation Biotechnologies Inc | METHOD FOR THE PREPARATION OF VESICLES |
ES2918381T3 (en) * | 2009-07-15 | 2022-07-15 | Glaxosmithkline Biologicals Sa | RSV F protein compositions and methods for producing the same |
SI2811981T1 (en) * | 2012-02-07 | 2019-08-30 | Infectious Disease Research Institute | Improved adjuvant formulations comprising tlr4 agonists and methods of using the same |
-
2016
- 2016-03-16 WO PCT/US2016/022711 patent/WO2016149417A1/en active Application Filing
- 2016-03-16 CN CN201680016531.7A patent/CN107405395A/en active Pending
- 2016-03-16 EP EP16765693.3A patent/EP3270962A4/en not_active Withdrawn
- 2016-03-17 CN CN201680016475.7A patent/CN107530418A/en active Pending
- 2016-03-17 WO PCT/US2016/022977 patent/WO2016149558A2/en active Application Filing
- 2016-03-17 EP EP16765794.9A patent/EP3270963A4/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030199071A1 (en) * | 2000-12-08 | 2003-10-23 | Solomon Langermann | Mutant proteins, high potency inhibitory antibodies and fimch crystal structure |
US20080131466A1 (en) * | 2006-09-26 | 2008-06-05 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
US20130273149A1 (en) * | 2012-04-12 | 2013-10-17 | Ac Immune Sa | Disaccharide synthetic lipid compounds and uses thereof |
WO2015044886A2 (en) * | 2013-09-25 | 2015-04-02 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
Non-Patent Citations (6)
Title |
---|
ANDERSON R C ET AL: "Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations", COLLOIDS AND SURFACES. B, BIOINTERFACES, ELSEVIER, AMSTERDAM, NL, vol. 75, no. 1, 1 January 2010 (2010-01-01), pages 123 - 132, XP026770794, ISSN: 0927-7765, [retrieved on 20090820], DOI: 10.1016/J.COLSURFB.2009.08.022 * |
AYESHA MISQUITH ET AL: "In vitro evaluation of TLR4 agonist activity: Formulation effects", COLLOIDS AND SURFACES. B, BIOINTERFACES, vol. 113, 1 January 2014 (2014-01-01), NL, pages 312 - 319, XP055270242, ISSN: 0927-7765, DOI: 10.1016/j.colsurfb.2013.09.006 * |
C. B. FOX ET AL: "Effects on Immunogenicity by Formulations of Emulsion-Based Adjuvants for Malaria Vaccines", CLINICAL AND VACCINE IMMUNOLOGY, vol. 19, no. 10, 1 October 2012 (2012-10-01), US, pages 1633 - 1640, XP055286524, ISSN: 1556-6811, DOI: 10.1128/CVI.00235-12 * |
HW MILLIE FUNG ET AL: "Optimizing manufacturing and composition of a TLR4 nanosuspension: physicochemical stability and vaccine adjuvant activity", JOURNAL OF NANOBIOTECHNOLOGY, BIOMED CENTRAL, GB, vol. 11, no. 1, 21 December 2013 (2013-12-21), pages 43, XP021172581, ISSN: 1477-3155, DOI: 10.1186/1477-3155-11-43 * |
LANGERMANN S ET AL: "VACCINATION WITH FIMH ADHESIN PROTECTS CYNOMOLGUS MONKEYS FROM COLONIZATION AND INFECTION BY UROPATHOGENIC ESCHERICHIA COLI", JOURNAL OF INFECTIOUS DISEASES. JID, UNIVERSITY OF CHICAGO PRESS, CHICAGO, IL, vol. 181, 1 February 2000 (2000-02-01), pages 774 - 778, XP002944650, ISSN: 0022-1899, DOI: 10.1086/315258 * |
RHEA N. COLER ET AL: "Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant", PLOS ONE, vol. 6, no. 1, 26 January 2011 (2011-01-26), pages e16333, XP055030261, DOI: 10.1371/journal.pone.0016333 * |
Also Published As
Publication number | Publication date |
---|---|
WO2016149558A2 (en) | 2016-09-22 |
EP3270963A2 (en) | 2018-01-24 |
WO2016149417A1 (en) | 2016-09-22 |
EP3270962A4 (en) | 2018-08-22 |
WO2016149558A3 (en) | 2017-03-23 |
EP3270962A1 (en) | 2018-01-24 |
CN107405395A (en) | 2017-11-28 |
CN107530418A (en) | 2018-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3049104A4 (en) | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections | |
EP3347469A4 (en) | Methods and compositions for the treatment of glaucoma | |
EP3390666A4 (en) | Compositions and methods for treatment of kidney diseases | |
HK1222398A1 (en) | Compositions and methods for the treatment of burkholderia infections | |
EP3157565A4 (en) | Treatment of polybacterials infections | |
EP3285874A4 (en) | Compositions and methods for treating mycobacteria infections and lung disease | |
EP3182989A4 (en) | Methods and compositions for the prevention and treatment of disease | |
EP3268007A4 (en) | Compositions and therapeutic methods for the treatment of complement-associated diseases | |
EP3280422A4 (en) | Compositions and methods for the treatment of hbv infection | |
EP3166615A4 (en) | Methods for the treatment of hepatitis b and hepatitis d virus infections | |
EP3442996A4 (en) | Methods of treatment using chlorotoxin conjugates | |
ZA201702884B (en) | Compositions and methods for the treatment and prophylaxis of surgical site infections | |
HK1252343A1 (en) | Compositions and methods for the treatment of viral infection | |
EP3518918A4 (en) | Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis | |
IL250596A0 (en) | A composition for the treatment and prevention of urinary tract infections | |
EP3419638A4 (en) | Compositions and methods of treatment of chronic infectious diseases | |
EP3426671A4 (en) | Compounds and compositions for the treatment of infections | |
EP3373922A4 (en) | Compositions and methods for treatment of homocystinuria | |
EP3341006A4 (en) | Compositions and methods for the treatment of neurodamage | |
EP3258908A4 (en) | Compositions and methods for treatment of skin infections | |
EP3509614A4 (en) | Methods and compositions for treatment of lafora disease | |
EP3538079A4 (en) | Compositions and methods for the treatment of oral infectious diseases | |
EP3139908A4 (en) | Formulations and methods for vaginal delivery of antiprogestins | |
EP3512550A4 (en) | Compositions and methods for treatment of enterovirus infection | |
EP3448377A4 (en) | Methods for the treatment of infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20171011 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20180719 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 39/02 20060101ALI20180713BHEP Ipc: A61K 9/00 20060101ALI20180713BHEP Ipc: A61K 39/108 20060101AFI20180713BHEP Ipc: A61K 39/39 20060101ALI20180713BHEP Ipc: A61K 39/00 20060101ALI20180713BHEP Ipc: A61K 31/7016 20060101ALI20180713BHEP |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SEQUOIA VACCINES, INC. |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SEQUOIA VACCINES, INC. |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20190219 |